South Korea’s health technology assessment body has approved three medical technologies for insurance coverage, marking a significant advancement in their evaluation framework. Among the approved tools is a quantitative blood test for tracking the JAK2 V617F mutation, crucial for diagnosing certain blood cancers, which will enable easier and more accessible monitoring. Additionally, a tablet-based cognitive screening test designed for use by general practitioners can assess cognitive impairment without neuropsychologist involvement, addressing an urgent need in the country’s aging population. Lastly, a platelet-rich fibrin treatment for jaw cysts has also been designated, broadening coverage for regenerative procedures in oral surgery. This move highlights South Korea’s commitment to integrating advanced medical evaluations and digital health tools into its insurance framework, setting a precedent for other systems globally.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.techtimes.com/articles/323970/20260811/blood-cancer-monitoring-tablet-dementia-screen-gain-korea-insurance-access.htm
